Articles with "investigational anti" as a keyword



KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases

Sign Up to like & get
recommendations!
Published in 2022 at "Expert Opinion on Investigational Drugs"

DOI: 10.1080/13543784.2022.2052042

Abstract: ABSTRACT Introduction KSI-301 is an intravitreal anti-vascular endothelial growth factor (VEGF) agent in clinical trials for the treatment of neovascular age-related macular degeneration (nAMD), diabetic retinopathy, diabetic macular edema (DME), and retinal vein occlusion (RVO).… read more here.

Keywords: ksi 301; vegf; anti vegf; investigational anti ... See more keywords
Photo from wikipedia

Investigational anti IL-13 asthma treatments: a 2023 update.

Sign Up to like & get
recommendations!
Published in 2023 at "Expert opinion on investigational drugs"

DOI: 10.1080/13543784.2023.2215425

Abstract: INTRODUCTION IL-13 is a pleiotropic type 2 cytokine important in the pathogenesis of asthma and other eosinophilic disorders. AREAS COVERED Different attempts to directly neutralise IL-13 or block its receptors and the possible impact that… read more here.

Keywords: 2023 update; asthma treatments; asthma; anti asthma ... See more keywords
Photo from wikipedia

Investigational Anti–Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?

Sign Up to like & get
recommendations!
Published in 2020 at "Journal of Cardiovascular Pharmacology"

DOI: 10.1097/fjc.0000000000000892

Abstract: Abstract: Antiarrhythmic drugs remain the mainstay therapy for patients with atrial fibrillation (AF). A major disadvantage of the currently available anti-AF agents is the risk of induction of ventricular proarrhythmias. Aiming to reduce this risk,… read more here.

Keywords: investigational anti; pharmacology; atrial fibrillation; anti atrial ... See more keywords
Photo by jontyson from unsplash

Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.

Sign Up to like & get
recommendations!
Published in 2020 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2020.38.15_suppl.tps3146

Abstract: TPS3146Background: While immune surveillance plays a critical role in preventing tumor proliferation and metastasis, tumors develop resistance mechanisms to suppress and/or escape the immune system... read more here.

Keywords: anti tim; antibody; a425 investigational; investigational anti ... See more keywords